<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292472</url>
  </required_header>
  <id_info>
    <org_study_id>MT_PRT_BMH01</org_study_id>
    <nct_id>NCT02292472</nct_id>
  </id_info>
  <brief_title>Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine Safety and Efficacy of Medytoxin® in Subjects in Benign Masseteric Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding
      Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric
      Hypertrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who voluntarily signed the informed consent and are judged to be eligible for this
      study will be intramuscularly injected with the study drug or the placebo to find appropreate
      dose for the treatment of Benign Masseteric Hypertrophy. Thereafter, follow-up visits will be
      made and efficacy and safety assessment will be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2014</start_date>
  <completion_date type="Actual">August 24, 2015</completion_date>
  <primary_completion_date type="Actual">May 24, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction amount of masseter muscle thickness</measure>
    <time_frame>after the injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction amount of masseter muscle thickness and lower face volume</measure>
    <time_frame>after the injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction of subject</measure>
    <time_frame>after the injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hypertrophy of Masseter Muscle</condition>
  <arm_group>
    <arm_group_label>Medytoxin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Inject intramuscularly once in visit 2</description>
    <arm_group_label>Medytoxin®</arm_group_label>
    <other_name>Medytoxin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Inject intramuscularly once in visit 2</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who shows benign masseteric hypertrophy

          2. Male or female subject over 19 years of age and written informed consent is obtained
             from the patient or LAR.

          3. Subject who has bisymmetry of masster at visual assessment.

          4. Subejects who qualifies the standard meets on ultrasonics wave value.

          5. Subjects who can and will comply with the requirements of the protocol.

        Exclusion Criteria:

          1. Diagnosis of myasthenia, facial palsy or severe facial asymmetry

          2. Subject who got any treatment, including double jaw surgery, laser, thread treatment
             etc. in 1 year.

          3. Subject who had previously received botulinum toxin within 3 months prior to the study
             entry

          4. Subject who is participating in other investigational study at present or 30 prior to
             the screening date.

          5. Subject with known hypersensitivity to botulinum toxin

          6. Subject who are pregnant or lactating or found pregnancy though the urine or sebum
             test or disagreed to avoid pregnancy during study preiod.

          7. Subjects who are not eligible for this study at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom Joon Kim, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungang university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>masticatory muscles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

